Eli Lilly (NYSE: LLY) Stock Analysis: Goldman Sachs Raises Price Target Amidst Weight-Loss Market Competition

• Eli Lilly (NYSE: LLY) receives an increased price target from Goldman Sachs, signaling potential upside in its stock performance.
• The pharmaceutical giant is a key player in the competitive and rapidly expanding weight-loss drug market, facing rivalry from Novo Nordisk (NYSE: NVO).
• Despite strong projected revenue growth, analysts anticipate a decline in earnings per share, highlighting the impact of market dynamics and competition.

Eli Lilly (NYSE: LLY), a leading pharmaceutical company, develops medicines for diabetes, obesity, and other critical conditions. It actively competes with Novo Nordisk (NYSE: NVO) in the rapidly expanding market for weight-loss treatments. Goldman Sachs (NYSE: GS) maintains a Buy rating on Eli Lilly stock and has raised its price target to $1,413.00 from $1,371.00. The shares traded at $1,297.84 when this analyst update was published on October 20, 2026.

This new price target represents $115.16 above the current share price, implying approximately 8.87% potential upside for Eli Lilly investors. It's important to remember that a price target reflects an analyst’s estimate of a stock's future value, not a guaranteed return. This optimistic target follows a strong month for Eli Lilly, even though its shares closed down 1.33% at $1,240.34 on October 19.

This slight decline for Eli Lilly occurred on a day when the S&P 500 index gained 0.41%. Nevertheless, over the preceding month, Eli Lilly stock demonstrated robust performance, rising 9.03% and significantly outperforming both the broader medical sector and the overall market. Investors are now keenly awaiting the company’s anticipated October 29 earnings report for further insights into its sales and profit growth.

According to Zacks, analysts project Eli Lilly's quarterly revenue to reach $22.11 billion, marking a substantial increase of 25.59% from the previous year. However, earnings per share (EPS) are expected to be $5.38 per share, representing a decline of 23.36%. As a key financial metric, earnings per share measures a company's profit divided by its outstanding shares. These forecasts indicate that while sales growth is strong, it doesn't automatically translate to higher profit per share, suggesting potential cost pressures or strategic investments.

Market competition remains a significant risk to Goldman Sachs’ optimistic outlook for Eli Lilly. As reported by 24/7 Wall Street, the potential for a price war with Novo Nordisk and Eli Lilly's reliance on a concentrated portfolio of products could impact future growth. Conversely, The Motley Fool highlights that Eli Lilly is successfully expanding its patient reach, even with lower prices per sale, while simultaneously improving its profit margins.